Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results
Background: The Hedgehog inhibitor sonidegib had durable efficacy and a manageable safety profile in patients with locally advanced basal cell carcinoma (laBCC) through 42 months of the BOLT trial. In this analysis, we characterize the effects of 200-mg and 800-mg sonidegib on tumors in patients in...
Saved in:
| Main Authors: | Michael R. Migden, Aaron S. Farberg, James Spencer, Felix Kiecker, Alexander Guminski, Kurt Gebauer, Carmen Loquai, Caroline Robert, Reinhard Dummer, Dirk Schadendorf, Axel Hauschild, Jean Jacques Grob, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Joerg Dierlamm, Ralf Gutzmer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824002556 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and economic benefits of using sonidegib in the 1-line therapy of patients with locally advanced basal cell carcinoma
by: O. I. Ivakhnenko, et al.
Published: (2025-08-01) -
Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib–Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management
by: Maha M. Ghalwash, et al.
Published: (2024-12-01) -
Locally advanced basal cell carcinoma in real life: Analysis of a cohort of 452 patients treated with systemic therapy from the CARADERM database
by: F. Herms, et al.
Published: (2025-01-01) -
Clinical outcomes and adverse events of Hedgehog pathway inhibitors for advanced basal cell carcinoma patients: A systematic review and meta-analysis
by: Suvijak Untaaveesup, et al.
Published: (2025-01-01) -
Immunohistochemical expression of smoothened in periocular basal cell, squamous cell and sebaceous carcinomas
by: Gustav Stålhammar, et al.
Published: (2025-06-01)